Development of a score model to predict long-term prognosis after community-onset pneumonia in older patients.

advance care planning antibiotic resistance community‐acquired pneumonia healthcare‐associated pneumonia long‐term prognosis pneumonia

Journal

Respirology (Carlton, Vic.)
ISSN: 1440-1843
Titre abrégé: Respirology
Pays: Australia
ID NLM: 9616368

Informations de publication

Date de publication:
20 May 2024
Historique:
received: 17 01 2024
accepted: 09 05 2024
medline: 21 5 2024
pubmed: 21 5 2024
entrez: 21 5 2024
Statut: aheadofprint

Résumé

The identification of factors associated with long-term prognosis after community-onset pneumonia in elderly patients should be considered when initiating advance care planning (ACP). We aimed to identify these factors and develop a prediction score model. Patients aged 65 years and older, who were hospitalized for pneumonia at nine collaborating institutions, were included. The prognosis of patients 180 days after the completion of antimicrobial treatment for pneumonia was prospectively collected. The total number of analysable cases was 399, excluding 7 outliers and 42 cases with missing data or unknown prognosis. These cases were randomly divided in an 8:2 ratio for score development and testing. The median age was 82 years, and there were 68 (17%) deaths. A multivariate analysis showed that significant factors were performance status (PS) ≥2 (Odds ratio [OR], 11.78), hypoalbuminemia ≤2.5 g/dL (OR, 5.28) and dementia (OR, 3.15), while age and detection of antimicrobial-resistant bacteria were not associated with prognosis. A scoring model was then developed with PS ≥2, Alb ≤2.5, and dementia providing scores of 2, 1 and 1 each, respectively, for a total of 4. The area under the curve was 0.8504, and the sensitivity and specificity were 94.6% and 61.7% at the cutoff of 2, respectively. In the test cases, the sensitivity and specificity were 91.7% and 63.1%, respectively, at a cutoff value of 2. Patients meeting this score should be considered near the end of life, and the initiation of ACP practices should be considered.

Sections du résumé

BACKGROUND AND OBJECTIVE OBJECTIVE
The identification of factors associated with long-term prognosis after community-onset pneumonia in elderly patients should be considered when initiating advance care planning (ACP). We aimed to identify these factors and develop a prediction score model.
METHODS METHODS
Patients aged 65 years and older, who were hospitalized for pneumonia at nine collaborating institutions, were included. The prognosis of patients 180 days after the completion of antimicrobial treatment for pneumonia was prospectively collected.
RESULTS RESULTS
The total number of analysable cases was 399, excluding 7 outliers and 42 cases with missing data or unknown prognosis. These cases were randomly divided in an 8:2 ratio for score development and testing. The median age was 82 years, and there were 68 (17%) deaths. A multivariate analysis showed that significant factors were performance status (PS) ≥2 (Odds ratio [OR], 11.78), hypoalbuminemia ≤2.5 g/dL (OR, 5.28) and dementia (OR, 3.15), while age and detection of antimicrobial-resistant bacteria were not associated with prognosis. A scoring model was then developed with PS ≥2, Alb ≤2.5, and dementia providing scores of 2, 1 and 1 each, respectively, for a total of 4. The area under the curve was 0.8504, and the sensitivity and specificity were 94.6% and 61.7% at the cutoff of 2, respectively. In the test cases, the sensitivity and specificity were 91.7% and 63.1%, respectively, at a cutoff value of 2.
CONCLUSION CONCLUSIONS
Patients meeting this score should be considered near the end of life, and the initiation of ACP practices should be considered.

Identifiants

pubmed: 38769707
doi: 10.1111/resp.14752
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

© 2024 Asian Pacific Society of Respirology.

Références

United Nations. World Population Prospects: The 2019 Revision.
Vital Statistics of the Ministry of Health. Labor and Welfare, Japan in 2022.
Givens JL, Jones RN, Shaffer ML, Kiely DK, Mitchell SL. Survival and comfort after treatment of pneumonia in advanced dementia. Arch Intern Med. 2010;170:1102–1107.
Carr D, Luth EA. Advance care planning: contemporary issues and future directions. Innov Aging. 2017;1:igx012.
Takazono T, Imamura Y, Kawakami K, Yamasaki N, Shimizu H, Usuki K, et al. Discrepancies in preferences regarding the care of terminal‐phase pneumonia in elderly patients among patients, families, and doctors: a multicenter questionnaire survey in Nagasaki, Japan. Respir Investig. 2020;58:488–494.
Morio R, Takazono T, Kubo R, Fukushima K, Suyama N, Izumikawa T, et al. Survey of advance care planning practices in elderly COVID‐19 patients: a multicenter questionnaire survey. Cureus. 2023;15:e39663.
Ishida T, Tachibana H, Ito A, Yoshioka H, Arita M, Hashimoto T. Clinical characteristics of nursing and healthcare‐associated pneumonia: a Japanese variant of healthcare‐associated pneumonia. Intern Med. 2012;51:2537–2544.
American Thoracic Society. Infectious Diseases Society of America. Guidelines for the management of adults with hospital‐acquired, ventilator‐associated, and healthcare‐associated pneumonia. Am J Respir Crit Care Med. 2005;171:388–416.
Fine MJ, Auble TE, Yealy DM, Hanusa BH, Weissfeld LA, Singer DE, et al. A prediction rule to identify low‐risk patients with community‐acquired pneumonia. N Engl J Med. 1997;336:243–250.
Miyashita N, Matsushima T, Oka M, Japanese Respiratory Society. The JRS guidelines for the management of community‐acquired pneumonia in adults: an update and new recommendations. Intern Med. 2006;45:419–428.
Holter JC, Ueland T, Jenum PA, Muller F, Brunborg C, Froland SS, et al. Risk factors for long‐term mortality after hospitalization for community‐acquired pneumonia: a 5‐year prospective follow‐up study. PLoS One. 2016;11:e0148741.
Noguchi S, Yatera K, Naito K, Hata R, Kawanami T, Yamasaki K, et al. Utility of the quick sequential organ failure assessment in Japanese patients with nursing‐ and healthcare‐associated pneumonia. Geriatr Gerontol Int. 2019;19:177–183.
Yamamoto M, Adachi H, Enomoto M, Fukami A, Nakamura S, Nohara Y, et al. Lower albumin levels are associated with frailty measures, trace elements, and an inflammation marker in a cross‐sectional study in Tanushimaru. Environ Health Prev Med. 2021;26:25.
Yanagita I, Fujihara Y, Iwaya C, Kitajima Y, Tajima M, Honda M, et al. Low serum albumin, aspartate aminotransferase, and body mass are risk factors for frailty in elderly people with diabetes‐a cross‐sectional study. BMC Geriatr. 2020;20:200.
Kulmala J, Nykanen I, Manty M, Hartikainen S. Association between frailty and dementia: a population‐based study. Gerontology. 2014;60:16–21.
Bai G, Wang Y, Kuja‐Halkola R, Li X, Tomata Y, Karlsson IK, et al. Frailty and the risk of dementia: is the association explained by shared environmental and genetic factors? BMC Med. 2021;19:248.
Francisco J, Aragao I, Cardoso T. Risk factors for long‐term mortality in patients admitted with severe infection. BMC Infect Dis. 2018;18:161.
Teramoto S, Fukuchi Y, Sasaki H, Sato K, Sekizawa K, Matsuse T, et al. High incidence of aspiration pneumonia in community‐ and hospital‐acquired pneumonia in hospitalized patients: a multicenter, prospective study in Japan. J Am Geriatr Soc. 2008;56:577–579.
Akata K, Yatera K, Yamasaki K, Kawanami T, Naito K, Noguchi S, et al. The significance of oral streptococci in patients with pneumonia with risk factors for aspiration: the bacterial floral analysis of 16S ribosomal RNA gene using bronchoalveolar lavage fluid. BMC Pulm Med. 2016;16:79.

Auteurs

Takahiro Takazono (T)

Department of Infectious Diseases, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan.
Department of Respiratory Medicine, Nagasaki University Hospital, Nagasaki, Japan.

Hotaka Namie (H)

Department of Infectious Diseases, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan.

Yohsuke Nagayoshi (Y)

Department of Respiratory Medicine, Japanese Red Cross Nagasaki Genbaku Isahaya Hospital, Isahaya, Japan.

Yoshifumi Imamura (Y)

Medical Education Development Center, Nagasaki University Hospital, Nagasaki, Japan.

Yuya Ito (Y)

Department of Respiratory Medicine, Nagasaki University Hospital, Nagasaki, Japan.

Makoto Sumiyoshi (M)

Division of Respirology, Rheumatology, Infectious Diseases, and Neurology, Department of Internal Medicine, University of Miyazaki, Miyazaki, Japan.

Nobuyuki Ashizawa (N)

Department of Respiratory Medicine, Nagasaki University Hospital, Nagasaki, Japan.

Masataka Yoshida (M)

Department of Respiratory Medicine, Nagasaki University Hospital, Nagasaki, Japan.

Kazuaki Takeda (K)

Department of Respiratory Medicine, Nagasaki University Hospital, Nagasaki, Japan.

Naoki Iwanaga (N)

Department of Respiratory Medicine, Nagasaki University Hospital, Nagasaki, Japan.

Shotaro Ide (S)

Department of Respiratory Medicine, Nagasaki University Hospital, Nagasaki, Japan.

Yosuke Harada (Y)

Department of Internal Medicine, Saiseikai Nagasaki Hospital, Nagasaki, Japan.

Naoki Hosogaya (N)

Clinical Research Center, Nagasaki University Hospital, Nagasaki, Japan.

Shinnosuke Takemoto (S)

Department of Respiratory Medicine, Nagasaki University Hospital, Nagasaki, Japan.

Yuichi Fukuda (Y)

Department of Respiratory Medicine, Sasebo City General Hospital, Sasebo, Japan.

Kazuko Yamamoto (K)

First Department of Internal Medicine, Division of Infectious, Respiratory, and Digestive Medicine, University of the Ryukyus Graduate School of Medicine Okinawa, Okinawa, Japan.

Taiga Miyazaki (T)

Division of Respirology, Rheumatology, Infectious Diseases, and Neurology, Department of Internal Medicine, University of Miyazaki, Miyazaki, Japan.

Noriho Sakamoto (N)

Department of Respiratory Medicine, Nagasaki University Hospital, Nagasaki, Japan.
Department of Respiratory Medicine, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan.

Yasushi Obase (Y)

Department of Respiratory Medicine, Nagasaki University Hospital, Nagasaki, Japan.
Department of Respiratory Medicine, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan.

Toyomitsu Sawai (T)

Department of Respiratory Medicine, Nagasaki Harbor Medical Center, Nagasaki, Japan.

Yasuhito Higashiyama (Y)

Department of Internal Medicine, Hokusho Central Hospital, Sasebo, Japan.

Kohji Hashiguchi (K)

Japanese Red Cross Nagasaki Genbaku Hospital, Nagasaki, Japan.

Satoshi Funakoshi (S)

Nagasaki Renal Center, Nagasaki, Japan.

Naofumi Suyama (N)

Department of Internal Medicine, Izumikawa Hospital, Minamishimabara, Japan.

Hikaru Tanaka (H)

Department of Internal Medicine, Senju Hospital, Sasebo, Japan.

Katsunori Yanagihara (K)

Department of Laboratory Medicine, Nagasaki University Hospital, Nagasaki, Japan.

Koichi Izumikawa (K)

Department of Infectious Diseases, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan.

Hiroshi Mukae (H)

Department of Respiratory Medicine, Nagasaki University Hospital, Nagasaki, Japan.
Department of Respiratory Medicine, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan.

Classifications MeSH